Total Payments
$1.2M
2024 Payments
$236,487
Companies
36
Transactions
1,382
Medicare Patients
4,518
Medicare Billing
$727,192
Payment Breakdown by Category
Other$682,800 (55.0%)
Consulting$246,099 (19.8%)
Research$153,370 (12.4%)
Travel$129,110 (10.4%)
Food & Beverage$26,388 (2.1%)
Education$3,716 (0.3%)
Gifts$35.33 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $674,540 | 228 | 54.3% |
| Consulting Fee | $246,099 | 98 | 19.8% |
| Unspecified | $153,370 | 66 | 12.4% |
| Travel and Lodging | $129,110 | 415 | 10.4% |
| Food and Beverage | $26,388 | 561 | 2.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,206 | 3 | 0.7% |
| Education | $3,716 | 8 | 0.3% |
| Entertainment | $54.72 | 2 | 0.0% |
| Gift | $35.33 | 1 | 0.0% |
Payments by Type
General
$1.1M
1,316 transactions
Research
$153,370
66 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $781,714 | 868 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $170,042 | 93 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $77,290 | 93 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $68,258 | 49 | $0 (2024) |
| Axsome Therapeutics, Inc. | $65,468 | 72 | $0 (2024) |
| Eisai Inc. | $45,672 | 66 | $0 (2023) |
| Merck Sharp & Dohme LLC | $13,952 | 45 | $0 (2023) |
| Arbor Pharmaceuticals, Inc. | $6,375 | 23 | $0 (2022) |
| Alkermes, Inc. | $4,560 | 2 | $0 (2023) |
| Daiichi Sankyo Inc. | $2,832 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236,487 | 171 | Takeda Pharmaceuticals U.S.A., Inc. ($147,280) |
| 2023 | $209,978 | 231 | JAZZ PHARMACEUTICALS INC. ($89,295) |
| 2022 | $157,531 | 154 | JAZZ PHARMACEUTICALS INC. ($107,840) |
| 2021 | $134,422 | 136 | JAZZ PHARMACEUTICALS INC. ($101,608) |
| 2020 | $106,003 | 154 | Jazz Pharmaceuticals Inc. ($65,231) |
| 2019 | $142,917 | 171 | JAZZ PHARMACEUTICALS INC. ($140,618) |
| 2018 | $117,566 | 142 | Jazz Pharmaceuticals Inc. ($114,807) |
| 2017 | $136,616 | 223 | Jazz Pharmaceuticals Inc. ($120,426) |
All Payment Transactions
1,382 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Insomnia | ||||||
| 12/18/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 12/13/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $1,503.00 | General |
| Category: Narcoplepsy | ||||||
| 12/12/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $751.50 | General |
| Category: Narcoplepsy | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $2.21 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Neurology | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $78.39 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: Immunology | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,390.00 | General |
| Category: NEUROLOGY | ||||||
| 11/25/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $36.14 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $107.74 | General |
| Category: NEUROLOGY | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Neurology | ||||||
| 11/19/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $34.68 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,503.00 | General |
| Category: Narcoplepsy | ||||||
| 11/13/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $1.62 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: NEUROLOGY | ||||||
| 10/16/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $751.50 | General |
| Category: Narcoplepsy | ||||||
| 10/03/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 10/02/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: NEUROLOGY | ||||||
| 09/25/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $44.14 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 09/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $1,216.07 | General |
| 09/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $55.43 | General |
| 09/19/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $90,397 | 12 |
| A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | Takeda Pharmaceuticals U.S.A., Inc. | $41,837 | 2 |
| A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | Takeda Pharmaceuticals U.S.A., Inc. | $9,425 | 3 |
| XP108 | ARBOR PHARMACEUTICALS, INC. | $2,500 | 2 |
| TAK-994: RESEARCH ACTIVITIES ACROSS OREXIN PROGRAM | Takeda Pharmaceuticals U.S.A., Inc. | $2,453 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $2,316 | 19 |
| A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | Takeda Pharmaceuticals U.S.A., Inc. | $1,858 | 5 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $1,156 | 12 |
| A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $836.61 | 2 |
| A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE | Takeda Pharmaceuticals U.S.A., Inc. | $261.26 | 5 |
| A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $239.34 | 1 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia IH With an Open-label Safety Extension | Jazz Pharmaceuticals Inc. | $80.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 1,745 | 2,560 | $895,499 | $262,094 |
| 2022 | 8 | 1,359 | 2,026 | $675,867 | $199,938 |
| 2021 | 8 | 740 | 1,048 | $419,422 | $132,909 |
| 2020 | 10 | 674 | 980 | $471,901 | $132,251 |
Total Patients
4,518
Total Services
6,614
Medicare Billing
$727,192
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,355 | 2,161 | $589,953 | $179,315 | 30.4% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 67 | 71 | $117,079 | $32,035 | 27.4% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 49 | 49 | $76,930 | $20,889 | 27.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 127 | 127 | $52,832 | $14,419 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 49 | $18,032 | $6,227 | 34.5% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 62 | 63 | $28,539 | $6,195 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $7,350 | $2,058 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 26 | $4,784 | $956.17 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 1,042 | 1,698 | $463,554 | $140,750 | 30.4% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 38 | 39 | $64,311 | $17,934 | 27.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 32 | 32 | $50,240 | $14,043 | 28.0% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2022 | 70 | 72 | $32,616 | $8,124 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 64 | 64 | $26,624 | $6,943 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 55 | $20,240 | $6,941 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 48 | $8,832 | $2,642 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $9,450 | $2,563 | 27.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 523 | 821 | $220,908 | $74,773 | 33.8% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 51 | 51 | $80,070 | $23,344 | 29.2% |
| 95811 | Sleep monitoring of patient (6 years or older) in sleep lab with continued pressured respiratory assistance by mask or breathing tube | Office | 2021 | 42 | 43 | $70,907 | $20,404 | 28.8% |
| 95800 | Study of sleep patterns, including sleep time | Office | 2021 | 37 | 39 | $17,667 | $4,759 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 29 | $10,214 | $3,765 | 36.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $7,875 | $2,321 | 29.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 24 | 29 | $7,917 | $2,263 | 28.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 21 | $3,864 | $1,279 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 378 | 675 | $182,860 | $51,017 | 27.9% |
About Dr. Richard Bogan, M.D
Dr. Richard Bogan, M.D is a Pulmonary Disease healthcare provider based in Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2008. The National Provider Identifier (NPI) number assigned to this provider is 1538347661.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Bogan, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $236,487 received in 2024. These payments were reported across 1,382 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($674,540).
As a Medicare-enrolled provider, Bogan has provided services to 4,518 Medicare beneficiaries, totaling 6,614 services with total Medicare billing of $727,192. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine
- Location Columbia, SC
- Active Since 01/31/2008
- Last Updated 02/23/2017
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1538347661
Products in Payments
- XYWAV (Drug) $283,827
- Xyrem (Drug) $193,607
- SUNOSI (Drug) $166,431
- XYREM (Drug) $79,682
- QUVIVIQ (Drug) $68,258
- Sunosi (Drug) $65,422
- Dayvigo (Drug) $43,932
- WAKIX (Drug) $39,893
- Wakix (Drug) $37,397
- BELSOMRA (Drug) $12,636
- Horizant (Drug) $6,350
- Somryst (Device) $1,700
- DUPIXENT (Biological) $211.02
- NIDRA (Device) $141.08
- BREZTRI (Drug) $125.00
- LUMRYZ (Drug) $102.71
- HETLIOZ (Drug) $76.02
- QELBREE (Drug) $74.09
- (9174) SPT (Device) $72.50
- SUVECALTAMIDE $69.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Columbia
Dr. Laura Herpel, M.d, M.D
Pulmonary Disease — Payments: $144,324
Pulmonary Disease $144,324
Dr. Carlton Cauthen, M.d, M.D
Pulmonary Disease — Payments: $116,511
Pulmonary Disease $116,511
Mr. Mark Mayson, Md, MD
Pulmonary Disease — Payments: $49,937
Pulmonary Disease $49,937
Edward Schaefer, Md, MD
Pulmonary Disease — Payments: $16,280
Pulmonary Disease $16,280
Jason Goodin, D.o, D.O
Pulmonary Disease — Payments: $14,722
Pulmonary Disease $14,722
Yuji Oba, M.d, M.D
Pulmonary Disease — Payments: $14,418
Pulmonary Disease $14,418